AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, engineered to reproduce the hormone's fat-reducing action while leaving its growth-promoting and glucose-disrupting effects behind. The proposed mechanism pairs two moves in fat tissue: stimulating lipolysis, the breakdown of stored fat, and inhibiting lipogenesis, the formation of new fat. That mechanistic story rests almost entirely on cell and rodent data, and a human obesity trial did not reproduce significant weight loss over placebo, so the cellular effects have not been confirmed to produce meaningful fat loss in people.
AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone (residues 176 to 191) proposed to reduce fat by stimulating lipolysis and inhibiting lipogenesis, though a phase 2 obesity trial found no statistically significant weight loss over placebo.
AOD-9604 is the last sixteen amino acids of human growth hormone, residues 176 to 191, the stretch of the molecule long identified as carrying its fat-reducing activity. Isolating that C-terminal segment was an attempt to keep the metabolic effect without the rest of the 191-amino-acid hormone. An extra tyrosine, not part of the natural sequence, was added to stabilize the peptide and to allow radiolabeling for research.
AOD-9604 is a roughly 1817-dalton synthetic peptide built from growth hormone residues 176 to 191 with an added tyrosine, produced by solid-phase peptide synthesis rather than the recombinant expression used for the full 22-kilodalton hormone.
Lipolysis is the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol that fat cells can release for energy. In cell and animal studies AOD-9604 has been reported to raise this activity in adipose tissue, reproducing an effect long attributed to growth hormone's C-terminal region. Investigators describe the fragment as mobilizing stored fat without the sustained growth hormone receptor signaling that drives the hormone's growth effects.
In isolated adipocytes and rodent obesity models, AOD-9604 has been reported to stimulate lipolysis with in vitro potency comparable to full-length growth hormone, but without engaging sustained growth hormone receptor signaling.
Where lipolysis empties the fat cell, an anti-lipogenic effect slows how quickly it refills. AOD-9604 is described in the preclinical literature as reducing lipogenesis, the conversion of excess carbohydrate and other substrates into triglycerides for storage. Pairing the two actions, promoting breakdown while suppressing synthesis, is the conceptual core of why the fragment was pursued as a weight-management candidate rather than a simple fat-burner.
AOD-9604's anti-lipogenic effect, the suppression of new triglyceride storage, is documented mainly in rodent models and adipocyte assays and, like its lipolytic effect, has not been confirmed in human clinical outcomes.
The beta-3 adrenergic receptor sits on the surface of fat cells and, when activated, triggers the cascade that drives lipolysis and heat-producing fat oxidation, which is why it has long been a target in obesity research. Studies of AOD-9604 implicate this pathway as a route for the fragment's metabolic effects, reporting that it acts through beta-3 signaling rather than the growth hormone receptor. Some preclinical work suggests the peptide can also raise beta-3 receptor expression, potentially increasing the tissue's capacity for fat oxidation over time.
Preclinical studies attribute AOD-9604's fat-metabolism activity to the beta-3 adrenergic receptor pathway rather than the growth hormone receptor, though whether the peptide acts on the receptor directly or indirectly has not been resolved.
Full-length growth hormone does more than break down fat: through the growth hormone receptor it drives IGF-1 release and can antagonize insulin, raising blood glucose with chronic exposure. The rationale for isolating the 176 to 191 fragment was that the hormone's lipolytic domain is structurally distinct from the regions responsible for growth and glucose signaling. In published animal and early human data, AOD-9604 did not significantly raise IGF-1 or worsen insulin sensitivity, a separation of effects presented as its key safety advantage, though drawn from limited rather than long-term human study.
| Effect | Full growth hormone | AOD-9604 (reported) |
|---|---|---|
| IGF-1 release | Stimulated via GH receptor | Not significantly raised |
| Insulin sensitivity | Reduced with chronic use | Not significantly impaired |
| Blood glucose | Can rise | Reported neutral |
| Lipolytic effect | Present | Retained |
In published animal and early human data, AOD-9604 reproduced growth hormone's lipolytic effect without significantly raising IGF-1 or impairing insulin sensitivity and blood glucose, the selective profile presented as its main safety advantage over the intact hormone.
The mechanistic case for AOD-9604 rests disproportionately on preclinical work, and the pivotal human test told a different story. A phase 2 obesity trial run by the developer did not show statistically significant weight loss over placebo, and development as an anti-obesity drug did not succeed, the single most important caveat on every fat-metabolism claim. The gap between promising cell and animal data and disappointing human outcomes is a familiar pattern in obesity pharmacology.
AOD-9604's fat-metabolism claims rest mainly on adipocyte and rodent data, while a developer-run phase 2 obesity trial found no statistically significant weight loss over placebo and the compound never gained approval as an obesity therapeutic.
Intact growth hormone is a 191-amino-acid protein that binds the growth hormone receptor to produce a broad set of actions: tissue growth, IGF-1 release, protein anabolism, and altered glucose handling, alongside its lipolytic effect. AOD-9604 was engineered to strip that package down to the fat-reducing element carried by the C-terminal 176 to 191 region. The intended difference is that the fragment reproduces the lipolytic and anti-lipogenic actions through pathways such as beta-3 signaling, without the receptor-mediated growth and IGF-1 responses of the whole hormone.
| Property | Intact growth hormone | AOD-9604 |
|---|---|---|
| Size | 191-amino-acid protein (~22 kDa) | 16-residue peptide (~1.8 kDa) |
| Production | Recombinant expression | Solid-phase synthesis |
| Primary receptor | Growth hormone receptor | Beta-3 adrenergic pathway (proposed) |
| IGF-1 and growth | Stimulated | Not driven |
| Metabolic reach | Systemic hormonal | Narrow, fat-focused |
AOD-9604 differs from intact growth hormone in size and pharmacology, a small synthetic peptide acting mainly through beta-3 adrenergic signaling on fat, engineered to capture the hormone's lipolytic effect without its growth-promoting, glucose-disrupting, and IGF-1-raising actions.
Educational use only. This article describes what the published scientific and clinical literature reports about AOD-9604. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
